Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joseph Bergman

Orthopaedic Surgery Kalispell, MT Medical Doctor

NPI 1285898569 CMS profile 542942

111 Sunnyview Ln, Kalispell, MT 59901

Open in the dashboard

General payments

$1,840

23 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joseph Bergman of Kalispell, MT is reported in the CMS Open Payments database as having received $1,840 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $324 3
2023 General $100 1
2022 General $59 1
2020 General $112 2
2019 General $1,246 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Bergman
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Joseph Bergman were reported at $0. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Joseph Bergman Orthopaedic Surgery median Middle half National median
2019 $1,246 $644 $140–$2,844 $163
2020 $112 $312 $75–$1,860 $114
2021 $0 $520 $117–$2,495 $132
2022 $59 $598 $128–$2,731 $149
2023 $100 $461 $128–$2,264 $160
2024 $324 $497 $134–$2,475 $164
2025 $0 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Stryker Corporation $1,583 20 payments
  2. Medacta USA, Inc. $144 1 payment
  3. DePuy Synthes Sales Inc. $113 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,071 16 payments
  2. Travel and Lodging $770 7 payments
Products named General payments · program years 2019–2024
  1. MAKO Knees, Hips $1,304 17 payments
  2. GMK Sphere Revision System $144 1 payment
  3. AXSOS $110 1 payment
  4. MAKO Knees, Hips $100 1 payment
  5. TRIATHLON Knees $79 1 payment
  6. INSIGNIA $70 1 payment
  7. TRIATHLON Knees $70 1 payment
  8. Velys $59 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

280

Median for Orthopedic Surgery: 203

Drug cost

$1,167

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 225 $599
Celecoxib Generic 29 $290
Diclofenac Sodium Generic 26 $277

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$275,006

Of which drugs: $10,478

Medicare patients

424

Average age 74

Services billed

11,669

228 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 58%
Depression 20%
Ischemic heart disease 16%
Diabetes 14%
Cancer 14%
Atrial fibrillation 13%
Osteoporosis 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 16 1,344 $9,386
Injection, methylprednisolone acetate, 1 mg J1010 Office 78 8,961 $925
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 15 $92
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 27 $74

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record